Clinical Trials
12
Active:0
Completed:7
Trial Phases
4 Phases
Phase 1:2
Phase 2:4
Phase 3:3
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)β’ Click on a phase to view related trials
Phase 2
4 (36.4%)Phase 3
3 (27.3%)Not Applicable
2 (18.2%)Phase 1
2 (18.2%)A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster
Not Applicable
Completed
- Conditions
- SARS-CoV-2 InfectionCOVID-19
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- WestVac Biopharma Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06381843
- Locations
- π¨π³
West China Hospital of Sichuan University, Chengdu, Sichuan, China
A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)
Phase 3
Recruiting
- Conditions
- COVID-19
- First Posted Date
- 2023-12-19
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- WestVac Biopharma Co., Ltd.
- Target Recruit Count
- 4800
- Registration Number
- NCT06175494
- Locations
- π¨π³
Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, China
A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination
Phase 2
Not yet recruiting
- Conditions
- COVID-19
- First Posted Date
- 2023-06-20
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- WestVac Biopharma Co., Ltd.
- Target Recruit Count
- 3100
- Registration Number
- NCT05911048
A Phase β ’ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination
Phase 3
Not yet recruiting
- Conditions
- COVID-19
- First Posted Date
- 2023-06-20
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- WestVac Biopharma Co., Ltd.
- Target Recruit Count
- 4950
- Registration Number
- NCT05911061
Phase II Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell)
Phase 2
Completed
- Conditions
- COVID-19
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- WestVac Biopharma Co., Ltd.
- Target Recruit Count
- 450
- Registration Number
- NCT05770180
- Locations
- π¨π³
Jiangsu Provincial Center for Disease Prevention and Control, Nanjing, China
- Prev
- 1
- 2
- 3
- Next
News
No news found